Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801063 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3453126 | 0.87 | PLA2G2C (0.35) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL801285 | 0.84 | ALDH1A1 (0.33) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3453311 | 0.84 | TRPV1 (0.36) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12344320 | 0.80 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL11911982 | 0.80 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12435119 | 0.80 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL29342180 | 0.79 | MLYCD (0.34) | SMN1; SMN2 | |
| SCHEMBL25015671 | 0.76 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL17777043 | 0.75 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ALDH1A1 1067/4885KDM4E 1291/4885MAPT 290/4885 |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | ALDH1A1 178/4885KDM4E 2762/4885MAPT 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.